Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 29, 2013

Idera, NCI to Pit TLR Antagonists against B-Cell Lymphomas

  • Idera Pharmaceuticals entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Cancer Institute (NCI) to evaluate the company’s Toll-like receptor (TLR) antagonists as a potential approach to the treatment of certain genetically defined B-cell lymphomas.

    Idera's technology platform, according to the firm, involves creating synthetic RNA- and DNA-based compounds to modulate immune responses. Idera has applied this platform to develop TLR antagonists as immunomodulatory drug candidates.

    Recently, Idera presented results of a Phase I trial of IMO-8400, an antagonist of TLRs 7, 8, and 9 being developed for potential applications in autoimmune and inflammatory diseases. In addition to being well tolerated at all dose levels, IMO-8400-treated subjects showed inhibition of TLR 7-, 8-, and 9-mediated cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interferon-alpha (IFN-α), and other pro-inflammatory cytokines. Another TLR antagonist, IMO-3100, is currently being tested in patients with moderate to severe plaque psoriasis.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »